by John Conrad | Aug 1, 2025 | Member News, NewsBrief
Chicago biotech startup ClostraBio has secured GRAS (Generally Recognized as Safe) status for its flagship probiotic ingredient CLB101™, clearing the path for the first commercially available strain of Anaerostipes caccae in the U.S. What Makes It Different Unlike...
by John Conrad | Dec 18, 2024 | iBIO in the News
iBIO President & CEO John Conrad recently had the pleasure of chatting with Kyle LaHucik to discuss the exciting developments in our biotech ecosystem. Many of you may have already seen his excellent article published yesterday in Endpoints News, which provides a...
by John Conrad | Oct 16, 2024 | iBIO News
In the heart of the Midwest, a technological revolution is brewing that could transform the landscape of pharmaceutical research. Chicago, long known for its towering skyscrapers and deep-dish pizza, is now poised to become the epicenter of a quantum-powered...
by John Conrad | Oct 4, 2024 | Uncategorized
Chicago-based biotech company receives FDA recognition for innovative spinal implant In a significant development for the field of regenerative medicine, Amphix Bio announced on October 3, 2024, that it has received Breakthrough Device designation from the U.S. Food...
by John Conrad | Sep 11, 2024 | NewsBrief
In a significant development for the healthcare industry, Chicago-based 32 Biosciences has announced its emergence from stealth mode, unveiling a groundbreaking approach to gut microbiome medicine. The company, whose name is pronounced “Three Squared...
